Question 1

What is Insulet's P/FCF ratio?

Accepted Answer

Insulet (PODD) P/FCF ratio is 27.1× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month free cash flow, using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/FCF ratio calculated?

Accepted Answer

P/FCF = Market Capitalisation ÷ Trailing Twelve-Month (TTM) Free Cash Flow, where Free Cash Flow = Operating Cash Flow − Capital Expenditures. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/FCF ratio?

Accepted Answer

The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.

Question 4

What is a good P/FCF ratio for Insulet?

Accepted Answer

Mature companies that consistently convert profit into cash often trade at 15–25× P/FCF; capital-intensive businesses with lumpy capex typically trade lower. Compare against sector peers and against the company's own multi-year average — single-year P/FCF can be distorted by working-capital swings. For Insulet specifically, the relevant sector benchmark is the current sector median of 19.1×.

Question 5

Is Insulet's P/FCF ratio high or low?

Accepted Answer

Insulet's P/FCF ratio of 27.1× is below its own 5-year average of 74.3× and above the sector median of 19.1×. That places the current reading at the 6th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Insulet's historical P/FCF ratio range?

Accepted Answer

In the available daily series, Insulet (PODD) P/FCF ratio has ranged from a low of 23.7× in 2026 to a high of 1654.6× in 2015. The 5-year average is 74.3× and the 5-year median is 64.4×.

Question 7

What was Insulet's P/FCF ratio in 2025?

Accepted Answer

Insulet (PODD) P/FCF ratio at the end of 2025 was 53.0×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month free cash flow figure available at that date.

Question 8

Why does Insulet's P/FCF ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (free cash flow). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$20B	$378M	53.0×	-9.9×	Dec 31, 2025
2024	$18.3B	$291M	62.9×	-153.4×	Dec 31, 2024
2023	$15.2B	$70.1M	216.2×	—	Dec 31, 2023
2022	$20.5B	-$38.3M	—	—	Dec 31, 2022
2021	$18.4B	-$191M	—	—	Dec 31, 2021
2020	$16.9B	-$82.4M	—	—	Dec 31, 2020
2019	$10.7B	-$71.2M	—	—	Dec 31, 2019
2018	$4.69B	-$126M	—	—	Dec 31, 2018
2017	$3.95B	-$36M	—	—	Dec 31, 2017
2016	$2.1B	-$6.2M	—	—	Dec 31, 2016
2015	$2.15B	-$23.2M	—	—	Dec 31, 2015
2014	$2.59B	-$2.57M	—	—	Dec 31, 2014
2013	$2.03B	-$3.96M	—	—	Dec 31, 2013
2012	$1.02B	-$40.1M	—	—	Dec 31, 2012
2011	$893M	-$36.6M	—	—	Dec 31, 2011
2010	$707M	-$42.2M	—	—	Dec 31, 2010
2009	$541M	-$52.5M	—	—	Dec 31, 2009
2008	$214M	-$92.7M	—	—	Dec 31, 2008
2007	$639M	-$60.5M	—	—	Dec 31, 2007
2006	$14.6M	—	—	—	Dec 31, 2006
2005	$12.7M	—	—	—	Dec 31, 2005


McKesson (MCK)	17.8×
Gilead Sciences (GILD)	16.9×
DexCom (DXCM)	16.9×
Pfizer (PFE)	16.7×
Humana (HUM)	16.4×
Quest Diagnostics (DGX)	16.3×
UnitedHealth Group (UNH)	15.9×
Labcorp Holdings (LH)	15.9×
Becton, Dickinson and (BDX)	14.0×
HCA Healthcare (HCA)	13.5×
Elevance Health (ELV)	13.4×
Incyte (INCY)	12.9×
CVS Health (CVS)	12.4×
Universal Health Services (UHS)	12.2×
Baxter International (BAX)	12.1×
Cardinal Health (CAH)	11.3×
IQVIA (IQV)	11.3×
Bristol-Myers Squibb (BMY)	10.4×
Biogen (BIIB)	10.3×
Zimmer Biomet Holdings (ZBH)	9.6×
Cigna (CI)	9.1×
Viatris (VTRS)	9.1×
DaVita (DVA)	6.9×
Teladoc Health (TDOC)	3.9×
Centene (CNC)	2.5×

P/FCF Ratio for Insulet (PODD) 2023-2026

P/FCF Ratio daily chart for Insulet (PODD)

Historical P/FCF Ratio for Insulet (PODD) from 2005 to 2025

About P/FCF Ratio at Insulet (PODD)

Insulet P/FCF Ratio by Year

Insulet P/FCF Ratio 2025: 53.0×

Insulet P/FCF Ratio 2024: 62.9×

Insulet P/FCF Ratio 2023: 216.2×

Sector peers by P/FCF Ratio — chart

Sector peers by P/FCF Ratio — table

Frequently asked questions

Insulet (PODD) Key Financials